Flashback Foreword: Prognostic Factors in Osteosarcoma.

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Prognostic Factors in High-Grade Osteosarcoma of theExtremities or Trunk: An Analysis of 1,702 Patients Treatedon Neoadjuvant Cooperative Osteosarcoma Study GroupProtocols. September 15, 2023 ARTICLE CITATION DOI: 10.1200/JCO.22.02860 Journal of Clinical Oncology - published online before print September 15, 2023 PMID: 37713811 Flashback Foreword: Prognostic Factors in Osteosarcoma Robert G. Maki , MD, PhD, FACP, FASCO1,2,3xRobert G. MakiSearch for articles by this author and Gary K. Schwartz, MD, FASCO1,4,5xGary K. SchwartzSearch for articles by this author Show More 1Associate Editor, Journal of Clinical Oncology, Alexandria, VA2University of Pennsylvania, Perelman School of Medicine, Abramson Cancer Center, Philadelphia, PA3Memorial Sloan-Kettering Cancer Center, New York, NY4Columbia University, Vagelos College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, New York, NY5Case Comprehensive Cancer Center, Cleveland, OH https://doi.org/10.1200/JCO.22.02860 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2002, Bielack et al1 reported on a large registry of patients with primary osteosarcoma treated from 1980 to 1998 with doxorubicin, cisplatin, and methotrexate-based therapy that describes many of the key clinical features of the diagnosis. Only modest changes in the standard of care since this paper's publication underscore the need for translation research to identify new therapeutic avenues to pursue.AUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Prognostic Factors in OsteosarcomaThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Robert G. MakiThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Employment: PEEL TherapeuticsConsulting or Advisory Role: Bayer, Deciphera, Ipsen, PEEL Therapeutics, UpToDateSpeakers' Bureau: MJH Life SciencesResearch Funding: Regeneron (Inst), Daiichi (Inst), Bayer (Inst), SpringWorks Therapeutics (Inst), Amgen (Inst), Astex Pharmaceuticals (Inst), Boehringer Ingelheim (Inst), Rain Therapeutics (Inst), BioAtla (Inst), C4 Therapeutics (Inst), Exelixis (Inst), InhibRx (Inst), PEEL Therapeutics (Inst), Regeneron (Inst), Presage Biosciences (Inst), SARC: Sarcoma Alliance for Research though Collaboration (Inst), SynOx (Inst), TRACON Pharma (Inst)Patents, Royalties, Other Intellectual Property: Uptodate: I write and edit chapters for their online text bookOpen Payments Link: https://openpaymentsdata.cms.gov/physician/205679Gary K. SchwartzThis author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Stock and Other Ownership Interests: GenCirq, Bionaut Labs, January TherapeuticsConsulting or Advisory Role: Bionaut Labs, Ellipses Pharma, Gencirq, Epizyme, Array BioPharma, Apexigen, Oncogenuity, OnCusp Therapeutics, Concarlo, Shanghai Pharma, Astex Pharmaceuticals, January Therapeutics, Sellas Life Sciences, PureTech, AADi, Kirilys Therapeutics, Agenus, Boehringer Ingelheim, IpsenResearch Funding: Astex Pharmaceuticals, Incyte (Inst), Calithera Biosciences (Inst), Lilly (Inst), Daiichi Sankyo (Inst), Fortress Biotech (Inst), Karyopharm Therapeutics (Inst), Oxford BioTherapeutics (Inst), Astex Pharmaceuticals (Inst), TopAlliance BioSciences Inc (Inst), Adaptimmune (Inst), SpringWorks Therapeutics (Inst), TRACON Pharma (Inst)Patents, Royalties, Other Intellectual Property: Companion diagnostics for CD4 inhibitors (Inst), patent granted to develop a new technology called PNAs for cancer therapyTravel, Accommodations, Expenses: Array BioPharma, Epizyme, Epizyme, Epizyme, Boehringer IngelheimNo other potential conflicts of interest were reported. Companion Prognostic Factors in High-Grade Osteosarcoma of theExtremities or Trunk: An Analysis of 1,702 Patients Treatedon Neoadjuvant Cooperative Osteosarcoma Study GroupProtocols